| Old Articles: <Older 25061-25070 Newer> |
|---|
 |
The Motley Fool
August 1, 2007
Anders Bylund |
Garmin Glitters: Fool by Numbers The GPS maker released second-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...   |
The Motley Fool
August 1, 2007
Lawrence Rothman |
Penske Automotive's Steady Drive Penske -- slow and steady wins the race. Investors, the company is diversified geographically, and that paid off with same-store revenue increasing 22.8% outside the U.S. |
The Motley Fool
August 1, 2007
Stan Huber |
Fool Exclusive: An Interview With inVentiv Health CEO Eran Broshy Here, the pharmaceutical staffing, sales, and communications provider's CEO discusses the company, its clients and its investment outlook. |
The Motley Fool
August 1, 2007
Brian Orelli |
RNAi Gets Pumped Up Is a collaboration between RNAi expert Alnylam Pharmaceuticals and medical-device maker Medtronic something investors can endorse? |
The Motley Fool
August 1, 2007
Brian Lawler |
CV Therapeutics' Turnaround Quarter Putting a close to a turnaround second quarter, CV Therapeutics announced its financial results recently. It looks like shareholders are in for some good times. |
The Motley Fool
August 1, 2007
Ryan Fuhrmann |
Buffalo Wild Wings Takes a Breather Investors weren't pleased with recent results, but the Buffalo Wild Wings story is far from over. |
The Motley Fool
August 1, 2007 |
InterNAP Awakens: Fool by Numbers The internet company released second-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
August 1, 2007 |
Navteq Heads North: Fool by Numbers The digital mapmaker released second-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
August 1, 2007
Billy Fisher |
Overseas Growth Sparks OSI's Earnings OSI Pharmaceuticals continues to prosper, and it has Tarceva to thank. But what happens when Tarceva becomes obsolete around 2009? Investors, take note. |
The Motley Fool
August 1, 2007
Lawrence Rothman |
Still Riding the Coach Coach continues to lead the charge, growing both its top and bottom lines better than 30%, yet it saw its stock price fall by 5%. |
| <Older 25061-25070 Newer> Return to current articles. |
